Epidemiology of Type 2 Diabetes

Textbook of Diabetes: Fourth Edition

Volumn , Issue , 2010, Pages 45-68

  Ma, Ronald C W ^a   Tong, Peter C Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

"impaired fasting glucose" (IFG); American Diabetes Association (ADA); Highly active antiretroviral therapy (HAART); Impaired glucose tolerance (IGT); National Health and Nutrition Examination Survey (NHANES I); Oral glucose tolerance testing (OGTT); Recent emerging risk factors; Risk factors for type 2 diabetes; Type 2 diabetes mellitus (T2DM)

Indexed keywords

EID: 84861875296     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444324808.ch4     Document Type: Chapter

References (233)

1. International Diabetes Federation. Diabetes Atlas, 4th edn. International Diabetes Federation, 2009.
2. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 (Suppl 1): S11-14.
3. Ma R, Chan J. Metabolic complications of obesity. In: Williams G, Fruhbeck G, eds. Obesity: Science to Practice. John Wiley & Sons Ltd, 2009: 235-270.
4. WHO Expert Consultation. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
5. Ramachandran A, Ma RC, Snehalatha DC. Diabetes in Asia. Lancet 2009 Oct 27. [Epub ahead of print].
6. Fujimoto WY, Bergstrom RW, Boyko EJ, Leonetti DL, Newell-Morris LL, Wahl PW. Susceptibility to development of central adiposity among populations. Obes Res 1995; 3 (Suppl 2): 179S-186S.
7. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD. The visceral adiposity syndrome in Japanese-American men. Obes Res 1994; 2: 364-371.
8. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 2001; 86: 5366-5371.
9. Ko GT, Liu KH, So WY, Tong PC, Ma RC, Ozaki R, et al. Cutoff values for central obesity in Chinese based on mesenteric fat thickness. Clin Nutr 2009 Jun 25. [Epub ahead of print]
10. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2006; 28: 2289-2304.
11. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008; 359: 61-73.
12. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999; 354: 1435-1439.
13. Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, Baldwin CM, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med 2005; 165: 863-867.
14. Ko GT, Chan JC, Chan AW, Wong PT, Hui SS, Tong SD, et al. Association between sleeping hours, working hours and obesity in Hong Kong Chinese: the "better health for better Hong Kong" health promotion campaign. Int J Obes (Lond) 2007; 31: 254-260.
15. Ayas NT, White DP, Al-Delaimy WK, Manson JE, Stampfer MJ, Speizer FE, et al. A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care 2003; 26: 380-384.
16. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, Pickering TG, et al. Sleep duration as a risk factor for diabetes incidence in a large US sample. Sleep 2007; 30: 1667-1673.
17. Ma RC, Kong AP, Chan N, Tong PC, Chan JC. Drug-induced endocrine and metabolic disorders. Drug Saf 2007; 30: 215-245.
18. Buchholz S, Morrow AF, Coleman PL. Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J 2008; 38: 602-606.
19. Gill GV, Mbanya JC, Ramaiya KL, Tesfaye S. A sub-Saharan African perspective of diabetes. Diabetologia 2009; 52: 8-16.
20. Jones OA, Maguire ML, Griffin JL. Environmental pollution and diabetes: a neglected association. Lancet 2008; 371: 287-288.
21. Lee DH, Steffes MW, Jacobs DR Jr. Can persistent organic pollutants explain the association between serum gamma-glutamyltransferase and type 2 diabetes? Diabetologia 2008; 51: 402-407.
22. Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, et al. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey, 1999-2002. Diabetes Care 2006; 29: 1638-1644.
23. Lee DH, Lee IK, Porta M, Steffes M, Jacobs DR Jr. Relationship between serum concentrations of persistent organic pollutants and the prevalence of metabolic syndrome among non-diabetic adults: results from the National Health and Nutrition Examination Survey, 1999-2002. Diabetologia 2007; 50: 1841-1851.
24. Lim JS, Lee DH, Jacobs DR Jr. Association of brominated flame retardants with diabetes and metabolic syndrome in the US population, 2003-2004. Diabetes Care 2008; 31: 1802-1807.
25. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C, et al. Fetal and infant growth and impaired glucose tolerance at age 64. Br Med J 1991; 303: 1019-1022.
26. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring of diabetic mothers: relationship to fetal hyperinsulinism. Diabetes Care 1995; 18: 611-617.
27. Tam WH, Ma RC, Yang X, Ko GT, Tong PC, Cockram CS, et al. Glucose intolerance and cardiometabolic risk in children exposed to maternal gestational diabetes mellitus in utero. Pediatrics 2008; 122: 1229-1234.
28. Ma RC, Chan JC. Pregnancy and diabetes scenario around the world: China. Int J Gynaecol Obstet 2009; 104: S42-S45.
29. Colagiuri S, Borch-Johnsen K, Glumer C, Vistisen D. There really is an epidemic of type 2 diabetes. Diabetologia 2005; 48: 1459-1463.
30. World Health Organization Expert Committee. Diabetes Mellitus, 1st report. Geneva: World Health Organization, 1965.
31. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. Br Med J 1998; 317: 371-375.
32. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care 1998; 21: 1686-1690.
33. Janus ED, Watt NMS, Lam KSL, Cockram CS, Siu STS, Liu LJ, et al. The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community based population study in Hong Kong Chinese. Diabet Med 2000; 17: 741-745.
34. Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 2000; 43: 1470-1475.
35. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 2007; 24: 333-343.
36. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Geneva, Switzerland: World Health Organization International Diabetes Federation, 2006.
37. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
38. Dowse GK, Zimmet PZ, King H. Relationship between prevalence of impaired glucose tolerance and NIDDM in a population. Diabetes Care 1991; 14: 968-974.
39. Motala AA. Diabetes trends in Africa. Diabetes Metab Res Rev 2002; 18 (Suppl 3): S14-20.
40. Dodu SR. Diabetes in the tropics. Br Med J 1967; 2: 747-750.
41. Mbanya JC, Kengne AP, Assah F. Diabetes care in Africa. Lancet 2006; 368: 1628-1629.
42. Herman WH, Ali MA, Aubert RE, Engelgau MM, Kenny SJ, Gunter EW, et al. Diabetes mellitus in Egypt: risk factors and prevalence. Diabet Med 1995; 12: 1126-1131.
43. Bouguerra R, Alberti H, Salem LB, Rayana CB, Atti JE, Gaigi S, et al. The global diabetes pandemic: the Tunisian experience. Eur J Clin Nutr 2007; 61: 160-165.
44. Amoah AG, Owusu SK, Adjei S. Diabetes in Ghana: a community based prevalence study in Greater Accra. Diabetes Res Clin Pract 2002; 56: 197-205.
45. Abubakari AR, Bhopal RS. Systematic review on the prevalence of diabetes, overweight/obesity and physical inactivity in Ghanaians and Nigerians. Public Health, 2008; 122: 173-182.
46. Mbanya JC, Ngogang J, Salah JN, Minkoulou E, Balkau B. Prevalence of NIDDM and impaired glucose tolerance in a rural and an urban population in Cameroon. Diabetologia 1997; 40: 824-829.
47. Levitt NS, Katzenellenbogen JM, Bradshaw D, Hoffman MN, Bonnici F. The prevalence and identification of risk factors for NIDDM in urban Africans in Cape Town, South Africa. Diabetes Care 1993; 16: 601-607.
48. Motala AA, Esterhuizen T, Gouws E, Pirie FJ, Omar MA. Diabetes and other disorders of glycemia in a rural South African community: prevalence and associated risk factors. Diabetes Care 2008; 31: 1783-1788.
49. Ramaiya KL, Swai AB, McLarty DG, Bhopal RS, Alberti KG. Prevalences of diabetes and cardiovascular disease risk factors in Hindu Indian subcommunities in Tanzania. Br Med J 1991; 303: 271-276..
50. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-1268.
51. Harris MI. Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the US population. Diabetes Care 1991; 14: 639-648.
52. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996:results from the San Antonio Heart Study. Arch Intern Med 1999; 159: 1450-1456.
53. Tucker KL, Bermudez OI, Castaneda C. Type 2 diabetes is prevalent and poorly controlled among Hispanic elders of Caribbean origin. Am J Public Health 2000; 90: 1288-1293.
54. Robbins JM, Vaccarino V, Zhang H, Kasl SV. Excess type 2 diabetes in African-American women and men aged 40-74 and socioeconomic status: evidence from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health 2000; 54: 839-845.
55. Knowler WC, Bennett PH, Hamman RF, Miller M. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978; 108: 497-505.
56. Harwell TS, McDowall JM, Moore K, Fagot-Campagna A, Helgerson SD, Gohdes D. Establishing surveillance for diabetes in American Indian youth. Diabetes Care 2001; 24: 1029-1032.
57. Pavkov ME, Hanson RL, Knowler WC, Bennett PH, Krakoff J, Nelson RG. Changing patterns of type 2 diabetes incidence among Pima Indians. Diabetes Care 2007; 30: 1758-1763.
58. Horn OK, Jacobs-Whyte H, Ing A, Bruegl A, Paradis G, Macaulay AC. Incidence and prevalence of type 2 diabetes in the First Nation community of Kahnawake, Quebec, Canada, 1986-2003. Can J Public Health 2007; 98: 438-443.
59. Grandinetti A, Chang HK, Mau MK, Curb JD, Kinney EK, Sagum R, et al. Prevalence of glucose intolerance among Native Hawaiians in two rural communities. Native Hawaiian Health Research (NHHR) Project. Diabetes Care 1998; 21: 549-554.
60. Fujimoto WY, Leonetti DL, Bergstrom RW, Kinyoun JL, Stolov WC, Wahl PW. Glucose intolerance and diabetic complications among Japanese-American women. Diabetes Res Clin Pract 1991; 13: 119-129.
61. Hara H, Egusa G, Yamakido M. Incidence of non-insulin-dependent diabetes mellitus and its risk factors in Japanese-Americans living in Hawaii and Los Angeles. Diabet Med 1996; 13 (Suppl 6): S133-1342.
62. Fujimoto WY, Bergstrom RW, Boyko EJ, Chen K, Kahn SE, Leonetti DL, et al. Type 2 diabetes and the metabolic syndrome in Japanese Americans. Diabetes Res Clin Pract 2000; 50 (Suppl 2): S73-76.
63. Hsu WC, Cheung S, Ong E, Wong K, Lin S, Leon K, et al. Identification of linguistic barriers to diabetes knowledge and glycemic control in Chinese Americans with diabetes. Diabetes Care 2006; 29: 415-416.
64. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001; 24: 1936-1940.
65. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
66. Dabelea D, Bell RA, D'Agostino RB Jr, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297: 2716-2724.
67. Perez-Bravo F, Carrasco E, Santos JL, Calvillan M, Larenas G, Albala C. Prevalence of type 2 diabetes and obesity in rural Mapuche population from Chile. Nutrition 2001; 17: 236-238.
68. Larenas G, Arias G, Espinoza O, Charles M, Landaeta O, Villanueva S, et al. [ Prevalence of diabetes mellitus in a Mapuche community of Region IX, Chile.] Rev Med Chil 1985; 113: 1121-1125.
69. Llanos G, Libman I. Diabetes in the Americas. Bull Pan Am Health Organ 1994; 28: 285-301.
70. Sanchez-Castillo CP, Velasquez-Monroy O, Lara-Esqueda A, Berber A, Sepulveda J, Tapia-Conyer R, et al. Diabetes and hypertension increases in a society with abdominal obesity: results of the Mexican National Health Survey 2000. Public Health Nutr 2005; 8: 53-60.
71. Aschner P, King H, Triana de Torrado M, Rodriguez BM. Glucose intolerance in Colombia: a population-based survey in an urban community. Diabetes Care 1993; 16: 90-93.
72. Malerbi DA, Franco LJ. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 yr. The Brazilian Cooperative Group on the Study of Diabetes Prevalence. Diabetes Care 1992; 15: 1509-1516.
73. Tulloch J. Diabetes in the Tropics. Churchill Livingstone, 1953.
74. Florey Cdu V, McDonald H, McDonald J, Miall WE. The prevalence of diabetes in a rural population of Jamaican adults. Int J Epidemiol 1972; 1: 157-166.
75. Florey CV. Blood sugar and serum insulin levels in Jamaica, West Indies. Adv Metab Disord 1978; 9: 65-91.
76. Cruickshank J, Riste L, Jackson M, Wilks R, Bennett F, Forrester T, et al. Standardized comparison of glucose tolerance and diabetes prevalence in 4 African/African-Carribean populations in Britain, Jamaica, and Cameroon. Diabet Med 1996; 13:S 18.
77. Wilks R, Rotimi C, Bennett F, McFarlane-Anderson N, Kaufman JS, Anderson SG, et al. Diabetes in the Caribbean: results of a population survey from Spanish Town, Jamaica. Diabet Med 1999; 16: 875-883.
78. Mather HM, Keen H. The Southall Diabetes Survey: prevalence of known diabetes in Asians and Europeans. Br Med J (Clin Res Ed) 1985; 291: 1081-1084.
79. Simmons D, Williams DR, Powell MJ. The Coventry Diabetes Study: prevalence of diabetes and impaired glucose tolerance in Europids and Asians. Q J Med 1991; 81: 1021-1030.
80. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 2001; 24: 1377-1383.
81. Wang J, Luben R, Khaw KT, Bingham S, Wareham NJ, Forouhi NG. Dietary energy density predicts the risk of incident type 2 diabetes: the European Prospective Investigation of Cancer (EPIC) Norfolk Study. Diabetes Care 2008; 31: 2120-2125.
82. McNaughton SA, Mishra GD, Brunner EJ. Dietary patterns, insulin resistance, and incidence of type 2 diabetes in the Whitehall II Study. Diabetes Care 2008; 31: 1343-1348.
83. Forouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet Med 2007; 24: 200-207.
84. Eliasson M, Lindahl B, Lundberg V, Stegmayr B. No increase in the prevalence of known diabetes between 1986 and 1999 in subjects 25-64 years of age in northern Sweden. Diabet Med 2002; 19: 874-880.
85. Yliharsila H, Lindstrom J, Eriksson JG, Jousilahti P, Valle TT, Sundvall J, et al. Prevalence of diabetes and impaired glucose regulation in 45-to 64-year-old individuals in three areas of Finland. Diabet Med 2005; 22: 88-91.
86. Vilbergsson S, Sigurdsson G, Sigvaldason H, Hreidarsson AB, Sigfusson N. Prevalence and incidence of NIDDM in Iceland: evidence for stable incidence among males and females 1967-1991: the Reykjavik Study. Diabet Med 1997; 14: 491-498.
87. Rajala U, Keinanen-Kiukaanniemi S, Uusimaki A, Reijula K, Kivela SL. Prevalence of diabetes mellitus and impaired glucose tolerance in a middle-aged Finnish population. Scand J Prim Health Care 1995; 13: 222-228.
88. Larsson H, Ahren B, Lindgarde F, Berglund G. Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle-aged women. J Intern Med 1995; 237: 537-541.
89. Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 2003; 26: 2335-2340.
90. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
91. Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 2008; 51: 2187-2196.
92. Lammi N, Taskinen O, Moltchanova E, Notkola IL, Eriksson JG, Tuomilehto J, et al. A high incidence of type 1 diabetes and an alarming increase in the incidence of type 2 diabetes among young adults in Finland between 1992 and 1996. Diabetologia 2007; 50: 1393-1400.
93. Muggeo M, Verlato G, Bonora E, Bressan F, Girotto S, Corbellini M, et al. The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia 1995; 38: 318-325.
94. Garancini MP, Calori G, Ruotolo G, Manara E, Izzo A, Ebbli E, et al. Prevalence of NIDDM and impaired glucose tolerance in Italy: an OGTT-based population study. Diabetologia 1995; 38: 306-313.
95. Bruno G, Merletti F, Bargero G, Melis D, Masi I, Ianni A, et al. Changes over time in the prevalence and quality of care of type 2 diabetes in Italy: the Casale Monferrato surveys, 1988 and 2000. Nutr Metab Cardiovasc Dis 2008; 18: 39-45.
96. Gourdy P, Ruidavets JB, Ferrieres J, Ducimetiere P, Amouyel P, Arveiler D, et al. Prevalence of type 2 diabetes and impaired fasting glucose in the middle-aged population of three French regions: the MONICA study 1995-97. Diabetes Metab 2001; 27: 347-358.
97. Defay R, Delcourt C, Ranvier M, Lacroux A, Papoz L. Relationships between physical activity, obesity and diabetes mellitus in a French elderly population: the POLA study. Pathologies Oculaires liees a l'Age. Int J Obes Relat Metab Disord 2001; 25: 512-518.
98. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, et al. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population: the Hoorn Study. Diabetes Care 1995; 18: 1270-1273.
99. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 2001; 285: 2109-2113.
100. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, Meyboom-de Jong B. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in the Netherlands (ZODIAC-1). Eur J Epidemiol 2003; 18: 793-800.
101. Katsilambros N, Aliferis K, Darviri C, Tsapogas P, Alexiou Z, Tritos N, et al. Evidence for an increase in the prevalence of known diabetes in a sample of an urban population in Greece. Diabet Med 1993; 10: 87-90.
102. Papazoglou N, Manes C, Chatzimitrofanous P, Papadeli E, Tzounas K, Scaragas G, et al. Epidemiology of diabetes mellitus in the elderly in northern Greece: a population study. Diabet Med 1995; 12: 397-400.
103. Lionis C, Bathianaki M, Antonakis N, Papavasiliou S, Philalithis A. A high prevalence of diabetes mellitus in a municipality of rural Crete, Greece. Diabet Med 2001; 18: 768-769.
104. Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. The epidemiology of type 2 diabetes mellitus in Greek adults: the ATTICA study. Diabet Med 2005; 22: 1581-1588.
105. Panagiotakos DB, Pitsavos C, Skoumas Y, Lentzas Y, Stefanadis C. Five-year incidence of type 2 diabetes mellitus among cardiovascular disease-free Greek adults: findings from the ATTICA study. Vasc Health Risk Manag 2008; 4: 691-698.
106. Erem C, Yildiz R, Kavgaci H, Karahan C, Deger O, Can G, et al. Prevalence of diabetes, obesity and hypertension in a Turkish population (Trabzon city). Diabetes Res Clin Pract 2001; 54: 203-208.
107. Kelestimur F, Cetin M, Pasaoglu H, Coksevim B, Cetinkaya F, Unluhizarci K, et al. The prevalence and identification of risk factors for type 2 diabetes mellitus and impaired glucose tolerance in Kayseri, central Anatolia, Turkey. Acta Diabetol 1999; 36: 85-91.
108. Panagiotakos DB, Tzima N, Pitsavos C, Chrysohoou C, Zampelas A, Toussoulis D, et al. The association between adherence to the Mediterranean diet and fasting indices of glucose homoeostasis: the ATTICA Study. J Am Coll Nutr 2007; 26: 32-38.
109. King H, Abdullaev B, Djumaeva S, Nikitin V, Ashworth L, Dobo MG. Glucose intolerance and associated factors in the Fergana Valley, Uzbekistan. Diabet Med 1998; 15: 1052-1062.
110. King H, Djumaeva S, Abdullaev B, Gacic Dobo M. Epidemiology of glucose intolerance and associated factors in Uzbekistan: a survey in Sirdaria province. Diabetes Res Clin Pract 2002; 55: 19-27.
111. Chazova LV, Kalinina AM, Markova EV, Pavlova LI. [Diabetes mellitus: its prevalence, relationship to the risk factors for IHD and prognostic importance (an epidemiological study).] Ter Arkh 1996; 68: 15-18.
112. State Science Research Centre of Preventive Medicine (Ministry of Health). Moscow Behavioural Factor Survey 2000-2001. Ministry of Health, 2002.
113. Perlman F, McKee M. Diabetes during the Russian transition. Diabetes Res Clin Pract 2008; 80: 305-313.
114. Szurkowska M, Szybinski Z, Nazim A, Szafraniec K, Jedrychowski W. [ Prevalence of type II diabetes mellitus in population of Krakow.] Pol Arch Med Wewn 2001; 106: 771-779.
115. International Diabetes Federation. Diabetes Atlas, 3rd edn. International Diabetes Federation, 2006.
116. Ahuja M. Epidemiological studies on diabetes mellitus in India. In: Ahuja M, ed. Epidemiology of Diabetes in Developing Countries. New Delhi: Interprint, 1979: 29-38.
117. Verma NP, Mehta SP, Madhu S, Mather HM, Keen H. Prevalence of known diabetes in an urban Indian environment: the Darya Ganj diabetes survey. Br Med J (Clin Res Ed) 1986; 293: 423-424.
118. Ramachandran A, Snehalatha C, Dharmaraj D, Viswanathan M. Prevalence of glucose intolerance in Asian Indians: urban-rural difference and significance of upper body adiposity. Diabetes Care 1992; 15: 1348-1355.
119. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001; 44: 1094-1101.
120. Mohan V, Deepa M, Deepa R, Shanthirani CS, Farooq S, Ganesan A, et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India: the Chennai Urban Rural Epidemiology Study (CURES-17). Diabetologia 2006; 49: 1175-1178.
121. Ramachandran A, Mary S, Yamuna A, Murugesan N, Snehalatha C. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care 2008; 31: 893-898.
122. Ramachandran A, Snehalatha C, Latha E, Manoharan M, Vijay V. Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population. Diabetes Res Clin Pract 1999; 44: 207-213.
123. Sadikot SM, Nigam A, Das S, Bajaj S, Zargar AH, Prasannakumar KM, et al. The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS). Diabetes Res Clin Pract 2004; 66: 301-307.
124. Mohan V, Deepa M, Anjana RM, Lanthorn H, Deepa R. Incidence of diabetes and pre-diabetes in a selected urban south Indian population (CUPS-19). J Assoc Physicians India 2008; 56: 152-157.
125. Ramachandran A, Snehalatha C, Vijay V, Wareham NJ, Colagiuri S. Derivation and validation of diabetes risk score for urban Asian Indians. Diabetes Res Clin Pract 2005; 70: 63-70.
126. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289-297.
127. Siegel K, Narayan KM, Kinra S. Finding a policy solution to India's diabetes epidemic. Health Aff (Millwood) 2008; 27: 1077-1090.
128. Shera AS, Rafique G, Khwaja IA, Ara J, Baqai S, King H. Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Shikarpur, Sindh Province. Diabet Med 1995; 12: 1116-1121.
129. Shera AS, Rafique G, Khawaja IA, Baqai S, King H. Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Baluchistan province. Diabetes Res Clin Pract 1999; 44: 49-58.
130. Shera AS, Jawad F, Maqsood A. Prevalence of diabetes in Pakistan. Diabetes Res Clin Pract 2007; 76: 219-222.
131. Sayeed MA, Khan AR, Banu A, Hussain MZ, Ali SM. Blood pressure and glycemic status in relation to body mass index in a rural population of Bangladesh. Bangladesh Med Res Counc Bull 1994; 20: 27-35.
132. Chandalia M, Abate N, Garg A, Stray-Gundersen J, Grundy SM. Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999; 84: 2329-2335.
133. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007; 125: 217-230.
134. Ramachandran A, Snehalatha C. Epidemiology of diabetes in South East Asia. In: Ekoe J-M, Rewers M, Williams R, Zimmet P, eds. The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester: John Wiley & Sons Ltd, 2008: 207-224.
135. Yajnik CS. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. J Nutr 2004; 134: 205-210.
136. Yajnik CS, Deshpande SS, Jackson AA, Refsum H, Rao S, Fisher DJ, et al. Vitamin B 12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia 2008; 51: 29-38.
137. Dowse GK, Gareeboo H, Zimmet PZ, Alberti KG, Tuomilehto J, Fareed D, et al. High prevalence of NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Mauritius Noncommunicable Disease Study Group. Diabetes 1990; 39: 390-396.
138. Soderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, et al. Increasing prevalence of type 2 diabetes mellitus in all ethnic groups in Mauritius. Diabet Med 2005; 22: 61-68.
139. Glans F, Elgzyri T, Shaat N, Lindholm E, Apelqvist J, Groop L. Immigrants from the Middle East have a different form of type 2 diabetes compared with Swedish patients. Diabet Med 2008; 25: 303-307.
140. Alwan A, King H. Diabetes in the Eastern Mediterranean (Middle East) region: the World Health Organization responds to a major public health challenge. Diabet Med 1995; 12: 1057-1058.
141. International Diabetes Institute. The Australian Diabetes, obesity and lifestyle study (AusDiab). Diabetes and Associated Disorders in Australia. Melbourne, Australia: International Diabetes Institute, 2001.
142. Glatthaar C, Welborn TA, Stenhouse NS, Garcia-Webb P. Diabetes and impaired glucose tolerance: a prevalence estimate based on the Busselton 1981 survey. Med J Aust 1985; 143: 436-440.
143. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829-834.
144. Magliano DJ, Shaw JE, Shortreed SM, Nusselder WJ, Liew D, Barr EL, et al. Lifetime risk and projected population prevalence of diabetes. Diabetologia 2008; 51: 2179-2186.
145. DeCourten M, Hodge AM, Dowse GK, King I, Vickery J, Zimmet P. Review of the epidemiology, aetiology, pathogenesis and preventability of diabetes in Aboriginal and Torres Strait Islander populations. Commonwealth of Australia: Office for Aboriginal and Torres Strait Islander Health Services, 1998.
146. Simmons D. The epidemiology of diabetes and its complications in New Zealand. Diabet Med 1996; 13: 371-375.
147. Ministry of Health NZ. A Portrait of Health: Key Results of the 2006/07 New Zealand Health Survey. 2008: 137-142.
148. Joshy G, Simmons D. Epidemiology of diabetes in New Zealand: revisit to a changing landscape. N Z Med J 2006; 119: U1999.
149. Dowse GK, Zimmet PZ, Finch CF, Collins VR. Decline in incidence of epidemic glucose intolerance in Nauruans: implications for the "thrifty genotype". Am J Epidemiol 1991; 133: 1093-1104.
150. Zimmet P, Taylor R, Ram P, King H, Sloman G, Raper LR, et al. Prevalence of diabetes and impaired glucose tolerance in the biracial (Melanesian and Indian) population of Fiji: a rural-urban comparison. Am J Epidemiol 1983; 118: 673-688.
151. King H, Finch C, Collins A, Koki G, King LF, Heywood P, et al. Glucose tolerance in Papua New Guinea: ethnic differences, association with environmental and behavioural factors and the possible emergence of glucose intolerance in a highland community. Med J Aust, 1989; 151: 204-210.
152. Dowse GK, Spark RA, Mavo B, Hodge AM, Erasmus RT, Gwalimu M, et al. Extraordinary prevalence of non-insulin-dependent diabetes mellitus and bimodal plasma glucose distribution in the Wanigela people of Papua New Guinea. Med J Aust 1994; 160: 767-774.
153. Collins VR, Dowse GK, Toelupe PM, Imo TT, Aloaina FL, Spark RA, et al. Increasing prevalence of NIDDM in the Pacific island population of Western Samoa over a 13-year period. Diabetes Care 1994; 17: 288-296.
154. Colagiuri S, Colagiuri R, Na'ati S, Muimuiheata S, Hussain Z, Palu T. The prevalence of diabetes in the kingdom of Tonga. Diabetes Care 2002; 25: 1378-1383.
155. Colagiuri S, Palu T, Viali S, Hussain Z, Colagiuri R. The epidemiology of diabetes in Pacific Island populations. In: Ekoe J-M, Rewers M, Williams R, Zimmet P, eds. The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester: John Wiley & Sons Ltd, 2008: 225-240.
156. Sekikawa A, Eguchi H, Tominaga M, Igarashi K, Abe T, Manaka H, et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in a rural area of Japan: the Funagata diabetes study. J Diabetes Complications 2000; 14: 78-83.
157. Ministry of Health Law. The Report of the National Diabetes Survey in 2002 [in Japanese]. 2002.
158. Owada M, Kitagawa T. Diabetes screening in school health system. Chiryo 1995; 77: 3047-3053.
159. Kitagawa T, Owada M, Urakami T, Yamauchi K. Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clin Pediatr (Phila) 1998; 37: 111-115.
160. Hara H, Egusa G, Yamakido M, Kawate R. The high prevalence of diabetes mellitus and hyperinsulinemia among the Japanese-Americans living in Hawaii and Los Angeles. Diabetes Res Clin Pract 1994; 24 (Suppl): S37-42.
161. Tajima N. Japan. In: Ekoe J-M, Rewers M, Williams R, Zimmet P, eds. The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester: John Wiley & Sons Ltd., 2008: 171-178.
162. Yazaki Y, Kadowaki T. Combating diabetes and obesity in Japan. Nat Med 2006; 12: 73-74.
163. Kim SM, Lee JS, Lee J, Na JK, Han JH, Yoon DK, et al. Prevalence of diabetes and impaired fasting glucose in Korea: Korean National Health and Nutrition Survey 2001. Diabetes Care 2006; 29: 226-231.
164. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688.
165. Cockram CS. The epidemiology of diabetes mellitus in the Asia-Pacific region. Hong Kong Med J 2000; 6: 43-52.
166. Hu YH, Li GW, Pan XR. [ Incidence of NIDDM in Daqing and forecasting of NIDDM in China in 21st century.] Zhonghua Nei Ke Za Zhi 1993; 32: 173-175.
167. Pan XR, Hu YH, Li GW, Liu PA, Bennett PH, Howard BV. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese: Da Qing IGT and diabetes study. Diabetes Care 1993; 16: 150-156.
168. Wang K, Li T, Xiang H. [Study on the epidemiological characteristics of diabetes mellitus and IGT in China.] Zhonghua Liu Xing Bing Xue Za Zhi 1998; 19: 282-285.
169. Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003; 46: 1190-1198.
170. Jia WP, Pang C, Chen L, Bao YQ, Lu JX, Lu HJ, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia 2007; 50: 286-292.
171. Janus E D, for the Hong Kong Cardiovascular Risk Factor Prevalence Study Group. Epidemiology of cardiovascular risk factors in Hong Kong. Clin Exp Pharmacol Physiol 1997; 24: 987-988.
172. Cockram CS, Woo J, Lau E, Chan JCN, Chan AYW, Lau J, et al. The prevalence of diabetes mellitus and impaired glucose tolerance among Hong Kong Chinese adults of working age. Diabetes Res Clin Pract 1993; 21: 67-73.
173. Chou P, Li CL, Kuo HS, Hsiao KJ, Tsai ST. Comparison of the prevalence in two diabetes surveys in Pu-Li, Taiwan, 1987-1988 and 1991-1992. Diabetes Res Clin Pract 1997; 38: 61-67.
174. Wong KC, Wang Z. Prevalence of type 2 diabetes mellitus of Chinese populations in Mainland China, Hong Kong, and Taiwan. Diabetes Res Clin Pract 2006; 73: 126-134.
175. Chan JC, Cockram CS. Epidemiology of diabetes mellitus in China. In: Ekoe J-M, Rewers M, Williams R, Zimmet P, eds. The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester: John Wiley and Sons Ltd, 2008: 179-206.
176. Li Y, Yang X, Zhai F, Piao J, Zhao W, Zhang J, et al. Childhood obesity and its health consequence in China. Obes Rev 2008; 9 (Suppl 1): 82-86.
177. Ko GT, Ozaki R, Wong GW, Kong AP, So WY, Tong PC, et al. The problem of obesity among adolescents in Hong Kong: a comparison using various diagnostic criteria. BMC Pediatr 2008; 8: 10.
178. Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM. National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 2003; 290: 1345-1350.
179. King H, Keuky L, Seng S, Khun T, Roglic G, Pinget M. Diabetes and associated disorders in Cambodia: two epidemiological surveys. Lancet 2005; 366: 1633-1639.
180. Duc Son LN, Kusama K, Hung NT, Loan TT, Chuyen NV, Kunii D, et al. Prevalence and risk factors for diabetes in Ho Chi Minh City, Vietnam. Diabet Med 2004; 21: 371-376.
181. Sutanegara D, Budhiarta AA. The epidemiology and management of diabetes mellitus in Indonesia. Diabetes Res Clin Pract 2000; 50 (Suppl 2): S9-S16.
182. Baltazar JC, Ancheta CA, Aban IB, Fernando RE, Baquilod MM. Prevalence and correlates of diabetes mellitus and impaired glucose tolerance among adults in Luzon, Philippines. Diabetes Res Clin Pract 2004; 64: 107-115.
183. Aekplakorn W, Abbott-Klafter J, Premgamone A, Dhanamun B, Chaikittiporn C, Chongsuvivatwong V, et al. Prevalence and management of diabetes and associated risk factors by regions of Thailand: Third National Health Examination Survey 2004. Diabetes Care 2007; 30: 2007-2012.
184. National Health Survey 2004. September 2005.
185. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 1998; 21: 1138-1145.
186. DECODE Study Group (Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe)/European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
187. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br Med J 2001; 322: 15-18.
188. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47: 385-394.
189. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care 2004; 27: 1605-1609.
190. McEwen LN, Kim C, Haan M, Ghosh D, Lantz PM, Mangione CM, et al. Diabetes reporting as a cause of death: results from the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 2006; 29: 247-253.
191. Morrish NJ, Wang S, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Survey of Vascular Diseases in Diabetes. Diabetologia 2001; 44 (Suppl 2): S14-21.
192. Keen H. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl 2): S1-2.
193. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: the Paris Prospective Study, ten years later. Horm Metab Res Suppl 1985; 15: 41-46.
194. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215-244.
195. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999; 91: 542-547.
196. Yang X, So W, Ko GT, Ma RC, Kong AP, Chow CC, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008; 179: 427-437.
197. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202.
198. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
199. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
200. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
201. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
202. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
203. Gulliford MC, Charlton J. Is relative mortality of type 2 diabetes mellitus decreasing? Am J Epidemiol 2009; 169: 455-461.
204. Ringborg A, Lindgren P, Martinell M, Yin DD, Schon S, Stalhammar J. Prevalence and incidence of type 2 diabetes and its complications 1996-2003: estimates from a Swedish population-based study. Diabet Med 2008; 25: 1178-1186.
205. Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study. Diabetes Care 2008; 31: 1761-1766.
206. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003; 26: 917-932.
207. Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004; 22: 149-164.
208. Economic costs of diabetes in the US in 2007. Diabetes Care 2008; 31: 596-615.
209. Zhang P, Engelgau MM, Norris SL, Gregg EW, Narayan KM. Application of economic analysis to diabetes and diabetes care. Ann Intern Med 2004; 140: 972-977.
210. Narayan KM, Zhang P, Williams D, Engelgau M, Imperatore G, Kanaya A, et al. How should developing countries manage diabetes? CMAJ 2006; 175: 733.
211. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-1679.
212. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783-1789.
213. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med, 2006; 166: 2191-2201.
214. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
215. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-1296.
216. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
217. Preiss D, Zetterstrand S, McMurray JJ, Ostergren J, Michelson EL, Granger CB, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care 2009; 32: 915-920.
218. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562.
219. Ekoe JM, Rewers M, Willaims R, Zimmet P. The Epidemiology of Diabetes Mellitus, 2nd edn. Chichester, UK: John Wiley & Sons Ltd, 2008.
220. Salti S, Khogali M, Alam S, Abu Haidar N, Masri A. Epidemiology of diabetes mellitus in relation to other cardiovascular risk factors in Lebanon. East Mediterr Health J 1997; 3: 462-471.
221. Al-Lawati JA, Al Riyami AM, Mohammed AJ, Jousilahti P. Increasing prevalence of diabetes mellitus in Oman. Diabet Med 2002; 19: 954-957.
222. Asfour MG, Lambourne A, Soliman A, Al-Behlani S, Al-Asfoor D, Bold A, et al. High prevalence of diabetes mellitus and impaired glucose tolerance in the Sultanate of Oman: results of the 1991 national survey. Diabet Med 1995; 12: 1122-1125.
223. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J 2004; 25: 1603-1610.
224. Al-Nuaim AR. Prevalence of glucose intolerance in urban and rural communities in Saudi Arabia. Diabet Med 1997; 14: 595-602.
225. Musaiger AO. Diabetes mellitus in Bahrain: an overview. Diabet Med 1992; 9: 574-578.
226. Narayan KMV, Zhang P, Kanaya AM, Williams DE, Engelgau MM, Impperatore G, Ramachandran A. Diabetes: the pandemic and potential solutions. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, eds. Disease Control and Priorities, 2nd edn. The International Bank of Reconstruction and Development/The World Bank, 2006.
227. Pan XR, Li GW, Hu YH, Yang WY, An ZX, Hu ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20 (4): 537-44.
228. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
229. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: A Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67: 152-162.
230. Wenying Y, Lixiang L, Jinwu Q, et al. The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multi-centre prospective study. Chin J Endocrinol Metab 2001; 17: 131-135.
231. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Prevention of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.
232. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368: 1096-1105.
233. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077.